ArticlePloS one2013
Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis.Neuro-oncology · 2015Pooled it
- Pre‑operative mean platelet volume is associated with overall survival in patients with IDH‑wildtype glioblastoma undergoing maximal safe resection.Oncology letters · 2024Article
- Significance of radiation therapy in frontal glioblastoma patients and exploration of optimal treatment modality: a real-world multiple-center study based on propensity score matching.Quantitative imaging in medicine and surgery · 2024Article
- scParser: sparse representation learning for scalable single-cell RNA sequencing data analysis.Genome biology · 2024Article
- Disclosing transcriptomics network-based signatures of glioma heterogeneity using sparse methods.BioData mining · 2023Article
- Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma.Heliyon · 2023Article
- Characteristic analysis and identification of novel molecular biomarkers in elderly glioblastoma patients using the 2021 WHO Classification of Central Nervous System Tumors.Frontiers in neuroscience · 2023Article
- Optimal managements of elderly patients with glioblastoma.Japanese journal of clinical oncology · 2022Review
- Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects.Biomedicines · 2022Review
- Radiomic Features Associated with Extent of Resection in Glioma Surgery.Acta neurochirurgica. Supplement · 2022Review
- Long Term Survivals in Aggressive Primary Brain Malignancies Treated With an Adjuvant Ketogenic Diet.Frontiers in nutrition · 2022Article
- A Deep Learning-Based Framework for Supporting Clinical Diagnosis of Glioblastoma Subtypes.Frontiers in genetics · 2022Article
- Identifying the miRNA Signature Association with Aging-Related Senescence in Glioblastoma.International journal of molecular sciences · 2021Article
- Integrative analysis identifies the association betweenNeurology. Genetics · 2020Article
- Whole-genome sequencing of glioblastoma reveals enrichment of non-coding constraint mutations in known and novel genes.Genome biology · 2020Article
- Negative binomial additive model for RNA-Seq data analysis.BMC bioinformatics · 2020Article
- Age-related Changes in the Global DNA Methylation Profile of Oligodendrocyte Progenitor Cells Derived from Rat Spinal Cords.Current medical science · 2019Article
- Aging in a Dish: iPSC-Derived and Directly Induced Neurons for Studying Brain Aging and Age-Related Neurodegenerative Diseases.Annual review of genetics · 2018Review
- Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme.G3 (Bethesda, Md.) · 2018Article
- Treatment of Glioblastoma in the Elderly.Drugs & aging · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
Age is a powerful predictor of survival in glioblastoma multiforme (GBM) yet the biological basis for the difference in clinical outcome is mostly unknown. Discovering genes and pathways that would explain age-specific survival difference could generate opportunities for novel therapeutics for GBM. Here we have integrated gene expression, exon expression, microRNA expression, copy number alteration, SNP, whole exome sequence, and DNA methylation data sets of a cohort of GBM patients in The Cancer Genome Atlas (TCGA) project to discover age-specific signatures at the transcriptional, genetic, and epigenetic levels and validated our findings on the REMBRANDT data set. We found major age-specific signatures at all levels including age-specific hypermethylation in polycomb group protein target genes and the upregulation of angiogenesis-related genes in older GBMs. These age-specific differences in GBM, which are independent of molecular subtypes, may in part explain the preferential effects of anti-angiogenic agents in older GBM and pave the way to a better understanding of the unique biology and clinical behavior of older versus younger GBMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.